Skip to main content
. Author manuscript; available in PMC: 2019 Aug 27.
Published in final edited form as: Cell Rep. 2019 Aug 13;28(7):1845–1859.e5. doi: 10.1016/j.celrep.2019.07.031

Figure 4. Loss of Drp1 Inhibits PDAC Progression.

Figure 4.

(A) Overall survival of Drp1WT (gray line) and Drp1flox/flox (black line) KPDC mice (n = 30 mice per group).

(B) Representative gross images of PDAC (black dashed outline) and liver metastases (white arrows).

(C) Tumor sections of indicated genotypes and stained with H&E. Scale bars, 300 μm.

(D) Drp1WT and Drp1flox/flox KPDC mice 40 days (left panel; n = 4 mice per genotype) or 60 days (right panel; n = 6 mice [Drp1WT]; 8 mice [Drp1flox/flox]) after tamoxifen injection quantified for all pancreatic lesions.

(E) Drp1 IHC of tumors. Low-magnification H&E (top row, left) and corresponding IHC images of tumor (top row, right). High-magnification IHC images from regions within tumors of the top panel (rows 2 and 4). Color-deconvoluted image of high-magnification IHC image (rows 3 and 5). Scale bars, 300 μm (rows 2–5); 2 mm (top row).

(F) Representative immunofluorescence analysis of mitochondrial morphology in pancreatic tumors harvested from Drp1WT and Drp1flox/flox mice and stained with an anti-mitochondria antibody (red) and DAPI (nuclei, blue). Insets, mitochondria magnified.